 Initiation of phase 1 study of first clinical drug AL044 targeting MS4A for Alzheimers Disease has been achieved. AbbVie for now remains committed with Alector in advancing AL002, which targets TREM2 for Alzheimers Disease, in the ongoing INVOKE-2 phase 2 study. 